Drugs / Mazdutide
Trials 35 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT06536023 | Aug 2024 → Jul 2025 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05793450 | May → Sep 2023 | impaired renal function disease | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05815680 | Apr → Aug 2023 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05623839 | Nov 2022 → Jun 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04773977 | Mar 2021 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03928379 | Oct 2019 → Jul 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03325387 | Oct 2017 → Aug 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02972645 | Dec 2016 → Jul 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07000955 | Jun 2025 → Sep 2026 expected | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06519656 | Oct 2024 → Dec 2025 overdue | polycystic ovary syndrome | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04466904 | Sep 2020 → May 2021 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04440345 | Jun 2020 → Jun 2021 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06937749 | Jul 2025 → Apr 2026 overdue | metabolic dysfunction-associated steatohepatitis | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06862908 | Apr 2025 → Sep 2026 expected | diastolic heart failure, mild heart failure, obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06817356 | Feb 2025 → Mar 2026 | alcohol-related disorders | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06124807 | Nov 2023 → Jan 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT04965506 | Sep 2021 → Apr 2022 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04904913 | Jun 2021 → Mar 2023 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT07469800 | Apr → Aug 2026 overdue | hypertensive disorder, obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07255209 | Dec 2025 → Oct 2027 expected | — | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07083154 | Sep 2025 → Aug 2029 expected | cognitive impairment with or without cerebellar ataxia, dementia, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 3 | NCT06931028 | Jun 2025 → May 2027 expected | obesity disorder, obstructive sleep apnea syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06884293 | May 2025 → Dec 2026 expected | metabolic dysfunction-associated steatotic liver disease, obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06184568 | Feb 2024 → Sep 2025 | obesity disorder, type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06164873 | Dec 2023 → Jun 2025 overdue | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05628311 | Jan → Oct 2023 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05606913 | Jan 2023 → Jan 2024 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05607680 | Nov 2022 → Aug 2023 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07654062 | Jul 2026 → Jun 2028 expected | prediabetes syndrome | Shandong Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07657676 | May 2026 → Oct 2027 expected | coronary atherosclerosis, obesity disorder | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07713992 | Sep 2026 → Dec 2027 expected | NAFLD1, type 2 diabetes mellitus | Tianjin Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07633639 | May 2026 → May 2028 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT07517042 | Apr 2026 → Dec 2028 expected | obesity disorder | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| — | NCT07135141 | Sep 2025 → Sep 2027 expected | morbid obesity | Beijing Friendship Hospital | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07417306 Comparator | Mar 2026 → Aug 2027 expected | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mazdutide | “Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 2022 |
| Known as | IBI362 | “Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 202220“Mazdutide (IBI362) is a GLP-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist.” NCT07654062 ↗ |
| Known as | LY3305677 | “We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) to evaluate the safety and efficacy of IBI362 (LY3305677), a GLP-1 and glucagon...” PMID 35750681 ↗ Jun 20226“Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 2022 |
| Known as | Mazdutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095358 ↗ |
| Action | Activate | “glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 2022 |
| Modality | Protein / enzyme biologic | — CHEMBL5095358 ↗ |
| Route | Subcutaneous | “Single escalating doses of LY3305677 administered subcutaneously (SC)” NCT02972645 ↗ |
| Target | GCGR | “GLP-1R and GCGR dual agonist” NCT06519656 ↗ |